drugset / Trial / NCT04173637
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multiple-center, randomized, double-blind, placebo-controlled Phase IIb study to evaluate the efficacy and safety of AK101, an anti-IL-12/23 p40 antibody, when administered subcutaneously, in subjects with moderate-to-severe plaque psoriasis. The study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blinded treatment and long-term follow-up period(up to 52 weeks).
Timeline
- Start
- 2019-12-19
- Primary completion
- 2022-03-03
- Completion
- 2022-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EBDAROKIMAB | Monoclonal antibody | 45 mg | Subcutaneous |
| Subject | EBDAROKIMAB | Monoclonal antibody | 90 mg | Subcutaneous |
| Subject | EBDAROKIMAB | Monoclonal antibody | 135 mg | Subcutaneous |